How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,763 results for

Aspartate Aminotransferase

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

(ALT) or aspartate aminotransferase (AST) > 3x upper limit of normal (ULN) confirmed on two consecutive measurements (by local laboratory) within 4 weeks prior to screening period Impaired excretory (e.g. hyperbilirubinemia) and/or synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites and bleeding from oesophageal varices. Acute viral or active autoimmune, alcoholic, or other types of hepatitis. Patients (...) Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2015 Clinical Trials

162. Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period. Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation [ Time Frame: Week 0, week 26 ] Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period. Change From Baseline in Total Bilirubin 26 Weeks After Randomisation [ Time Frame: Week 0, week 26 ] Week 26 data are based on the last (...) Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2015 Clinical Trials

163. Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2015 Clinical Trials

164. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. (Abstract)

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Plasma aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) are usually increased in patients with nonalcoholic fatty liver disease (NAFLD). However, the factors behind their elevation remain unclear. The aim of this study was to assess the role of insulin resistance (IR) and liver triglyceride content in relation to histology (...) . Consistent with the (1)H-MRS data, steatosis on liver biopsy was also significantly increased in patients with NASH and elevated ALT levels (P < 0.0001). However, and most important, there were no differences in inflammation (P = 0.62), ballooning (P = 0.13), or fibrosis (P = 0.12).In patients with NAFLD or NASH, ATIR (but not HIR) and liver triglyceride content are major factors in the elevation of plasma aminotransferase levels. Patients with normal versus elevated ALT had similar severity of NASH

2014 Hepatology

165. Advanced Hepatic Fibrosis and Steatosis Are Associated with Persistently Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for HCV RNA During Pegylated Interferon Plus Ribavirin Therapy. Full Text available with Trip Pro

% vs 74.0%; P = .0002). Multivariate analyses showed that body mass index ≥ 27 kg/m(2), ALT level ≥3 times the upper limit of normal, aspartate aminotransferase to platelet ratio index score ≥1.5, hepatic fibrosis ≥F3, and hepatic steatosis ≥S2 were independent factors associated with POAE after viral clearance.POAE is common in CHC patients during therapy. HCV-1 patients with POAE have a lower SVR rate to 48-week therapy if they achieve complete EVR. Advanced hepatic fibrosis, obesity (...) Advanced Hepatic Fibrosis and Steatosis Are Associated with Persistently Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for HCV RNA During Pegylated Interferon Plus Ribavirin Therapy. Clinical implications of persistent alanine aminotransferase (ALT) elevation and associated factors in chronic hepatitis C (CHC) patients who achieved undetectable hepatitis C virus (HCV) RNA during pegylated interferon plus ribavirin (peg-IFN/RBV) therapy remain unknown.A total

2014 Journal of Infectious Diseases

166. Can aminotransferase to platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Full Text available with Trip Pro

aspartate aminotransferase (P = 0.007), bilirubin (P ≤ 0.001), platelet count (P = 0.01) and APRI (P ≤ 0.001). The use of any one laboratory abnormality to predict liver biopsy scores did not show high positive predictive values (22.6-72.7%). Having abnormal liver findings or cirrhosis on imaging was associated with high specificities (92.0-97.8%) but low sensitivities (31.4-42.9%). Using APRI levels of ≥0.40 and ≤0.95 as an indication for liver biopsy, 50% of patients with F3-F4 would have correctly (...) Can aminotransferase to platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Advanced fibrosis or cirrhosis is still regarded as a contraindication for kidney transplantation alone by most centers. The value of aminotransferase to platelet ratio index (APRI) and other non-invasive markers has been less studied in hepatitis C virus (HCV)-positive patients with concurrent end-stage renal

2013 Transplantation

167. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Full Text available with Trip Pro

were enrolled to study. Patients were randomized to one of the following treatments for 6 months: Group I, probiotic (Protexin two tablets per day) plus Metformin 500 mg two tablets per day (Met/Pro), or group II, Metformin 500 mg two tablets per day plus two placebo tablet (Met/P). After 6 month alanine aminotransferase (ALT), aspartate aminotransferase, and ultrasound grading of NASH were assessed.IN GROUP I, SERUM ALANINE AMINOTRANSFERASE (ALT: 133.7 ± 70 vs. 45.2 ± 32.5; P < 0.00 (...) ), and aspartate aminotransferase activity (AST: 123.1 ± 72 vs. 44.2 ± 33.9; P < 0.001), and ultrasound grading of NASH (P < 0.001) all decreased significantly by the end of the treatment period. In group II, while serum alanine aminotransferase (ALT) was not significantly reduced (118.4 ± 67.9 vs. 112.5 ± 68.7; P < 0.064), aspartate aminotransferase activity (AST: 125.3 ± 71 vs. 113.4 ± 71; P < 0.001), and ultrasound grading of NASH did fall significantly (P < 0.01). Body mass index (BMI), fasting blood sugar

2013 International journal of preventive medicine Controlled trial quality: uncertain

168. PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population. Full Text available with Trip Pro

was corrected by the genotyping of 103 ancestry informative markers (AIMs) for Mexican Americans.Both PNPLA3 SNPs showed highly significant association with alanine aminotransferase (ALT) levels, but was also, in males, associated with aspartate aminotransferase (AST) levels. Haplotypic association test of the two SNPs suggested stronger genetic association with rs738409 than rs2281135. Obvious sex effects were observed: rs738409-sex interaction in ALT levels P = 8.37 x 10(-4); rs738409-sex interaction (...) PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population. This study examined genetic associations of patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and liver aminotransferases in an extensively documented, randomly recruited Mexican American population at high risk of liver disease.Two single nucleotide polymorphisms (SNP) in the PNPLA3 gene (i.e., rs738409 and rs2281135) were genotyped in 1532 individuals. Population stratification

2012 Clinical and investigative medicine. Médecine clinique et experimentale Controlled trial quality: uncertain

169. Aminotransferase Levels Are Associated With Cardiometabolic Risk Above and Beyond Visceral Fat and Insulin Resistance: The Framingham Heart Study. Full Text available with Trip Pro

to those without diabetes mellitus. Similar trends were observed for aspartate aminotransferase levels, but associations were more modest.Aminotransferase levels are correlated with multiple cardiometabolic risk factors above and beyond visceral adipose tissue and insulin resistance. (...) Aminotransferase Levels Are Associated With Cardiometabolic Risk Above and Beyond Visceral Fat and Insulin Resistance: The Framingham Heart Study. We sought to characterize associations between aminotransferase levels and cardiometabolic risk after accounting for visceral adipose tissue and insulin resistance.Participants (n=2621) from the Framingham Heart Study (mean age 51, 49.8% women) were included. Sex-specific linear and logistic regressions were used to evaluate associations between

2012 Thrombosis and Vascular Biology

170. MOLECULAR MODELING AND FUNCTIONAL CONFIRMATION OF A PREDICTED FATTY ACID BINDING SITE OF MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE Full Text available with Trip Pro

MOLECULAR MODELING AND FUNCTIONAL CONFIRMATION OF A PREDICTED FATTY ACID BINDING SITE OF MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE Molecular interactions are necessary for proteins to perform their functions. The identification of a putative plasma membrane fatty acid transporter as mitochondrial aspartate aminotransferase (mAsp-AT) indicated that the protein must have a fatty acid binding site. Molecular modeling suggests that such a site exists in the form of a 500-Å(3) hydrophobic cleft

2011 Journal of Molecular Biology

171. Genome-wide association study identifies genetic variants in GOT1 determining serum aspartate aminotransferase levels Full Text available with Trip Pro

Genome-wide association study identifies genetic variants in GOT1 determining serum aspartate aminotransferase levels We carried out a genome-wide association study of serum aspartate aminotransferase (AST) activity in 866 Amish participants of the Heredity and Phenotype Intervention Heart Study and identified significant association of AST activity with a cluster of single nucleotide polymorphisms located on chromosome 10q24.1 (peak association was rs17109512; P=2.80E-14), in the vicinity

2011 Journal of Human Genetics

172. Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis Full Text available with Trip Pro

Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis 22087195 2011 11 23 2018 11 13 1735-3408 11 7 2011 Jul Hepatitis monthly Hepat Mon Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis. 560-1 Sirli Roxana R Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara, Romania. Sporea Ioan I eng Journal Article Iran (...) Hepat Mon 101277874 1735-143X Aspartate aminotransferase Chronic hepatitis Liver fibrosis 2011 04 09 2011 04 12 2011 04 15 2011 11 17 6 0 2011 11 17 6 0 2011 11 17 6 1 ppublish 22087195 PMC3212765 Hepat Mon. 2011 Feb;11(2):103-6 22087126 J Hepatol. 2009 Jan;50(1):165-73 18977552 Hepatology. 2007 Sep;46(3):912-21 17705266 Ann Hepatol. 2008 Oct-Dec;7(4):350-7 19034235 Aliment Pharmacol Ther. 2011 Feb;33(4):455-65 21235598 Clin Chim Acta. 2011 Jan 14;412(1-2):33-7 20828546 Dig Dis Sci. 2011 Sep;56(9

2011 Hepatitis monthly

173. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. (Abstract)

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. Noninvasive tests that can be used in place of liver biopsy to diagnose fibrosis have major limitations. They either leave a significant proportion of patients without a definitive diagnosis or produce inaccurate results. Moreover, the performance of these tests is lower in HIV/hepatitis C virus (HCV) coinfection. Against (...) characteristic curve (AUROC). Positive (PPV) and negative (NPV) predictive values were calculated.Ninety patients were included in the study. Aspartate aminotransferase (AST), platelet count and MMP-2 were predictors of significant fibrosis (F≥2) and cirrhosis (F4). A score constructed using these variables yielded an AUROC of 0.76 for F≥2 and 0.88 for F4. Score cut-offs detected (value ≥3.5) and excluded (value ≤1.5) F≥2 with a PPV of 87% and an NPV of 88%. Thirty-one patients (34%) were correctly diagnosed

2011 HIV medicine

174. Purification and characterization of kynurenine--2-oxoglutarate aminotransferase from the liver, brain and small intestine of rats. Full Text available with Trip Pro

and polyacrylamide-disc-gel electrophoresis, it is suggested that liver, brain and small intestinal kynurenine-2-oxoglutarate aminotransferase (isoenzyme 1) is identical with mitochondrial tyrosine-2-oxoglutarate aminotransferase and also with mitochondrial aspartate-2-oxoglutarate aminotransferase. 2. An additional kynurenine-2-oxoglutarate aminotransferase (isoenzyme 2) was purified from the liver. This enzyme was specific for 2-oxoglutarate and L-kynurenine. Sucrose-density-gradient centrifugation gave (...) Purification and characterization of kynurenine--2-oxoglutarate aminotransferase from the liver, brain and small intestine of rats. 1. Kynurenine-2-oxoglutarate aminotransferase (isoenzyme 1) was purified to homogeneity from the liver, brain and small intestine of rats by the same procedure. The three enzyme preparations had nearly identical pH optima, substrate specificities and molecular weights. Isoenzyme 1 was active with 2-oxoglutarate but not with pyruvate as amino acceptor, and utilized

1975 Biochemical Journal

175. Activity of aminotransferases in the tissues of developing lambs. Full Text available with Trip Pro

Activity of aminotransferases in the tissues of developing lambs. 5360690 1970 02 05 2018 11 13 0264-6021 115 5 1969 Dec The Biochemical journal Biochem. J. Activity of aminotransferases in the tissues of developing lambs. 39P-40P Smith E M EM Shepherd D A DA Jeacock M K MK eng Journal Article England Biochem J 2984726R 0264-6021 EC 2.6.1.1 Aspartate Aminotransferases EC 2.6.1.2 Alanine Transaminase IM Alanine Transaminase analysis Animals Animals, Newborn Aspartate Aminotransferases analysis

1969 Biochemical Journal

176. Hepatocyte differentiation in culture. Appearance of tyrosine aminotransferase. Full Text available with Trip Pro

Hepatocyte differentiation in culture. Appearance of tyrosine aminotransferase. Liver of rat foetuses from 14 to 19 days of gestation and cultured hepatocytes derived from foetuses of 14 or 15 days gestation show a limited capacity to transaminate tyrosine. This low tyrosine transamination activity can be ascribed to aspartate aminotransferase. Definitive tyrosine aminotransferase can be demonstrated in 1-day-old cultures of hepatocytes taken from 19-day foetuses, but not from 15-day foetuses (...) . However, after 3 days of culture hepatocytes from 15-day foetuses are able to synthesize tyrosine aminotransferase. Induction studies reveal that dexamethasone is capable of increasing tyrosine aminotransferase activity once it is detectable in culture.

1979 Biochemical Journal

177. Active-site-directed irreversible inhibition of rat brain 4-aminobutyrate aminotransferase by ethanolamine O-sulphate in vitro and in vivo Full Text available with Trip Pro

=7.15x10(-4)s(-1)). The inclusion of 4-aminobutyrate markedly slowed the rate of inactivation. 3. Ethanolamine O-sulphate did not inhibit glutamate decarboxylase, alanine aminotransferase or aspartate aminotransferase. 4. Intracisternal injection of ethanolamine O-sulphate into rats led to rapid inactivation of 4-aminobutyrate aminotransferase in vivo. (...) Active-site-directed irreversible inhibition of rat brain 4-aminobutyrate aminotransferase by ethanolamine O-sulphate in vitro and in vivo 1. Partially purified preparations of rat brain 4-aminobutyrate aminotransferase were inhibited in a time-dependent manner by ethanolamine O-sulphate. The inhibition was not reversed by dialysis. 2. The inhibitor formed an initial reversible complex with the enzyme (K(i)=4.4x10(-4)m) and the rate of inactivation followed pseudo-first-order kinetics (k

1972 Biochemical Journal

178. RELATIONSHIP OF A β-ALANINE-PYRUVIC AMINOTRANSFERASE TO REVERSAL OF d-SERINE INHIBITION OF GROWTH Full Text available with Trip Pro

Pantothenic Acid 30KYC7MIAI Aspartic Acid 452VLY9402 Serine 50SG953SK6 Mitomycin 5V5IOJ8338 Pyridoxal Phosphate 6Q205EH1VU Vancomycin 95IK5KI84Z Cycloserine EC 2.6.1.- Transaminases EC 2.6.1.2 Alanine Transaminase OF5P57N2ZX Alanine OM Alanine Alanine Transaminase Aspartic Acid Cycloserine Flavobacterium Ketoglutaric Acids Mitomycin Mitomycins Pantothenic Acid Penicillins Pharmacology Pyridoxal Phosphate Pyruvates Research Serine Transaminases Vancomycin beta-Alanine ALANINE ALANINE AMINOTRANSFERASE (...) RELATIONSHIP OF A β-ALANINE-PYRUVIC AMINOTRANSFERASE TO REVERSAL OF d-SERINE INHIBITION OF GROWTH 14234816 1996 12 01 2018 12 01 0021-9193 88 1964 Nov Journal of bacteriology J. Bacteriol. RELATIONSHIP OF A BETA-ALANINE-PYRUVIC AMINOTRANSFERASE TO REVERSAL OF D-SERINE INHIBITION OF GROWTH. 1525-6 DURHAM N N NN JACOBS C D CD FERGUSON D D eng Journal Article United States J Bacteriol 2985120R 0021-9193 0 Ketoglutaric Acids 0 Mitomycins 0 Penicillins 0 Pyruvates 11P2JDE17B beta-Alanine 19F5HK2737

1964 Journal of bacteriology

179. Inhibition of alanine aminotransferase by L-penicillamine. Full Text available with Trip Pro

Inhibition of alanine aminotransferase by L-penicillamine. 5767039 1969 04 18 2018 11 13 0264-6021 111 3 1969 Feb The Biochemical journal Biochem. J. Inhibition of alanine aminotransferase by L-penicillamine. 15P-16P Evered D F DF Hargreaves B M BM Verjee Z H ZH eng Journal Article England Biochem J 2984726R 0264-6021 EC 2.6.1.1 Aspartate Aminotransferases EC 2.6.1.2 Alanine Transaminase GNN1DV99GX Penicillamine IM Alanine Transaminase antagonists & inhibitors Animals Aspartate (...) Aminotransferases metabolism In Vitro Techniques Myocardium enzymology Penicillamine pharmacology Plants enzymology Rats Swine 1969 2 1 1969 2 1 0 1 1969 2 1 0 0 ppublish 5767039 PMC1187537 Hoppe Seylers Z Physiol Chem. 1968 Mar;349(3):310-6 5725541 Arch Biochem Biophys. 1957 May;68(1):69-75 13435895 Arch Biochem Biophys. 1957 Jul;69:130-7 13445187 J Biol Chem. 1950 May;184(1):63-70 15421973

1969 Biochemical Journal

180. [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]. (Abstract)

to consciousness, blood ammonia, the liver function markers alanine aminotransferase, gamma-glutamyl-transpeptidase and total bilirubin, and the neuropeptides arginine vasopressin and beta-endorphin were remarkably improved after treatment in the research group, as compared with that in the control group.Supplementing the traditional treatment for hepatic encephalopathy with ornithine aspartate plus naloxone combination therapy provides better therapeutic outcome than traditional treatment alone. (...) [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]. To investigate the potential effects on cognitive function, prognosis, and neuropeptide levels of patients in response to combination therapy with ornithine aspartate plus naloxone for hepatic encephalopathy.Eighty-four consecutive patients diagnosed with hepatic encephalopathy were randomly divided into two equal groups. The control group (n = 42

2013 Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>